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Studies of human genetics and pathophysiology have implicated
the regulation of autophagy in inflammation, neurodegeneration,
infection, and autoimmunity. These findings have motivated the use
of small-molecule probes to study how modulation of autophagy
affects disease-associated phenotypes. Here, we describe the
discovery of the small-molecule probe BRD5631 that is derived from
diversity-oriented synthesis and enhances autophagy through an
mTOR-independent pathway. We demonstrate that BRD5631 af-
fects several cellular disease phenotypes previously linked to
autophagy, including protein aggregation, cell survival, bacterial
replication, and inflammatory cytokine production. BRD5631 can
serve as a valuable tool for studying the role of autophagy in the
context of cellular homeostasis and disease.
high-throughput screening | autophagy | small-molecule probes |
Crohn’s disease
Macroautophagy (hereafter autophagy), an evolutionarilyconserved catabolic process in which cytosolic content is
engulfed and degraded in lysosomes, has been implicated in
several human diseases, including inflammatory disorders such as
Crohn’s disease (CD), immune responses to Mycobacterium tu-
berculosis (Mtb), α1-antitrypsin deficiency, nonalcoholic fatty liver
disease, and neurodegenerative disorders (1). Autophagy is fre-
quently initiated by ULK1-mediated phosphorylation of Beclin1,
leading to activation of the lipid kinase VPS34, which in turn leads
to engagement of two ubiquitin (Ub)-like conjugation systems that
modify ATG12 and ATG8 (LC3) to trigger expansion of auto-
phagosomal membranes (2). Once initiated, degradation by
autophagy can be either nonselective for bulk intracellular com-
ponents (canonical) or selective for cargo such as damaged or-
ganelles (mitophagy), invasive pathogens (xenophagy), or protein
aggregates (aggrephagy) (3).
Although many types of cells use autophagy, disease phenotypes
linked to autophagy-related genes are often restricted primarily to
specific organ systems. CD-associated genetic variants that regu-
late autophagy have been linked to phenotypes involving the in-
testinal epithelium and cytokine-producing innate immune cells
that may reflect high microbial load. More specifically, disease-
associated alleles in genes that regulate bacterial recognition
(NOD2, IRGM) and autophagy (ATG16L1) are associated with
reduced clearance of intracellular bacteria (4). Furthermore, ex-
pression of a coding variant in ATG16L1 (T300A) correlates
with compromised bacterial defense, increased release of in-
flammatory cytokines (IL-1β), and reduced formation of anti-
microbial granules in gut Paneth cells (5, 6). Similar organ-
associated phenotypes have been observed for variants linked to
other diseases. Mutations in the autophagy geneWDR45 have been
associated with static encephalopathy of childhood with generation
in adulthood (SENDA), and SENDA disease phenotypes (iron
accumulation and cerebral atrophy) appear to be restricted to
the brain despite WDR45 expression in skeletal muscle (7).
Brain-related disease phenotypes have also been observed in
patients with a form of hereditary spastic paraparesis bearing a
recessive mutation in the putative autophagy regulator TECPR2,
and in patients suffering from cerebellar atrophy associated with
mutations in the autophagy modulator SNX14 (8, 9).
Small-molecule enhancers of autophagy are increasingly being
tested for their beneficial effects on disease phenotypes in relevant
organ systems and cell types (10). For example, different en-
hancers exhibit distinct profiles of activity in innate and adaptive
immune pathways, including host defense against pathogens
(11). Phenothiazine-derived antipsychotics (prochlorperazine
edisylate) and first-line antibiotics (isoniazid and pyrazinamide)
promote autophagy-dependent activity against Mtb, the latter
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involving modulation of proinflammatory responses in Mtb-in-
fected macrophages (12, 13). Likewise, the autophagy-inducing
peptide Tat-Beclin1 enhances autophagy-dependent antiviral
activity in cell and animal models (14). In the context of protein
aggregation disorders, carbamazepine (CBZ)-induced autophagy
reduces accumulation of α1-antitrypsin in liver cells and rescues
hepatic fibrosis in mice (15), whereas rapamycin- or trehalose-
induced autophagy clears α-synuclein and mutant huntingtin ag-
gregates in neurodegenerative disease models, among others (16).
Autophagy defects linked to the lysosomal storage disorder
Niemann–Pick type C1 disease (NPC1; caused by mutation in
the NPC1 protein) can be restored by stimulating autophagy
with rapamycin or CBZ, which is cytoprotective in NPC1 disease-
relevant cells (17, 18). In the context of CD, small molecules have
been shown to promote favorable immune phenotypes. Treat-
ment with the PDK1 inhibitor AR-12 in macrophages (19) or
rapamycin in epithelial cells (20) promotes bacterial clearance,
and treatment with rapamycin leads to reduced IL-1β levels in
innate immune cells and animals, possibly via degradation of
pro-IL-1β or its processing machinery (21).
Though modulating the mTOR pathway appears to affect
disease phenotypes in several contexts, mTOR signaling is also
critical for nutrient sensing, cell growth, and other fundamental
processes. For several reasons, it may be beneficial to avoid
perturbation of this critical cellular pathway in treating disease;
for example, its inhibition has also been linked to infection (22).
Additional small molecules have been shown to induce auto-
phagy independently of mTOR (e.g., trifluoperazine, niguldipine,
ABT-737). These compounds span a range of annotated protein
targets and signaling pathways, but the relevance of the anno-
tated targets to promotion of autophagy often remains un-
defined and may in some cases constitute impediments for
further development (1, 10). Identification of small-molecule
modulators of canonical and selective autophagy in disease-
relevant cell types with novel and distinct mechanisms of action
will contribute to studying the relevance of autophagy in disease
and the potential of autophagy enhancement as a therapeutic
strategy.
Here, we describe the identification of novel enhancers of
autophagy using a high-throughput screen (HTS) of 59,541 small
molecules prepared by stereoselective diversity-oriented chemical
synthesis (23). We demonstrate that representative hits promote
autophagy without perturbing mTOR signaling or lysosomal
function, and display autophagy-dependent activity in a number of
disease-relevant models, including suppression of NPC1-triggered
apoptosis in human induced pluripotent stem cell (hiPSC)-derived
neurons, enhancement of bacterial colocalization with autophagic
markers and clearance in epithelial cells, and suppression of mi-
crobial product-mediated IL-1β secretion by macrophages. One
probe, BRD5631, is capable of rescuing defects in bacterial
colocalization with LC3 and suppressing IL-1β production in cells
harboring the CD-associated allele of ATG16L1 (T300A). BRD5631
and related compounds constitute a novel set of mTOR-independent
autophagy probes for studying the regulation of autophagy and its
impact on disease pathways.
Results
High-Throughput Screening Identifies Novel Small-Molecule Modulators
of Autophagy. To discover novel small-molecule modulators of ca-
nonical autophagy, we performed a HTS of 59,541 stereochemi-
cally and skeletally diverse compounds derived from diversity-
oriented synthesis (DOS). These molecules are enriched for
sp3-hybridized atoms relative to conventional commercial libraries
(24–26), resulting in topographically rich 3D structures. The pri-
mary HTS measured autophagosome number in HeLa cells stably
expressing GFP-LC3 (Fig. 1A). LC3 normally displays a diffuse
cytosolic pattern (LC3-I), but upon induction of autophagy, LC3 is
posttranslationally modified (LC3-II) and accumulates on auto-
phagosome membranes. This change can be visualized and
quantified by counting the number of GFP-LC3 punctae per
cell by microscopy (27). Significance of changes was assessed by
comparing the distribution of punctae per cell for each compound
(test distribution) to that of DMSO (null distribution), and com-
puting the area under the curve of the test distribution beyond
the critical value corresponding to 95% confidence of the null
distribution.
To assess data quality, we confirmed that the distributions of
punctae per cell for the negative control (DMSO) and the positive
control (PI-103, a dual mTOR/PI3K inhibitor) showed strong and
statistically significant separation. Typically, ∼70% of PI-103–
treated cells exhibited numbers of punctae per cell greater than
the 95% critical threshold for the DMSO distribution. We
identified ∼2,000 hits that increased the average number of GFP-
LC3 punctae per cell to a level ≥30% of the positive control
(background-subtracted). A total of 998 of these hits were selected
based on activity and structure and tested for effects on viability of
HeLa cells (72-h treatment) using CellTiter-Glo; 85% of hits
showed little to modest toxicity (<25% effect) at 10 μM (data
not shown).
The number of GFP-LC3 punctae in the cell can be increased
by either activating autophagy or by inhibiting autophagy at late
steps in the process, such as by disrupting lysosome function. We
prioritized 400 representative hits based on potency and chem-
ical structure for testing in a secondary assay for autophagosome
formation and maturation (flux) that relies on visualizing LC3
protein tagged with both mCherry and GFP. The GFP signal is
attenuated in autolysosomes, while the mCherry signal remains
stable (28); as a result, autophagosomes (GFP+/mCherry+) and
autolysosomes (GFP−/mCherry+) can be distinguished and counted
by high-throughput imaging (SI Appendix, Fig. S1). The number of
GFP−/mCherry+ punctae (presumed autolysosomes) was increased
by 250 hits (putative activators) and decreased by 80 hits (putative
late-stage inhibitors) from the primary screen.
In analyzing the screening data, we noted that the hit rate for
compounds having an alkyl amine (7%) was higher than that for
all compounds (3%), an effect enhanced by the additional pres-
ence of a single lipophilic group, such as diphenyl alkyne (61%),
biphenyl (26%), cyclohexane (21%), or naphthalene (37%) (SI
Appendix, Fig. S2). By preparing and testing analogs of a potent
hit, BRD5631 (Fig. 1 B and C), we confirmed that both structural
features were important for its activity. Only analogs containing an
amine retained activity, and both removal of the terminal phenyl
group and its replacement with a pyridyl group eliminated
activity of BRD5631. Compounds containing a lipophilic group
and a basic amine can accumulate within lysosomes (lysosomo-
tropism) and potentially interfere with lysosomal function, cell
viability, and autophagy (29, 30). To determine whether our hits
disrupt lysosomal function, we first tested their effect on lysosomal
proteases by measuring processing of a fluorogenic substrate (DQ-
BSA) (31). For these experiments, we selected four structurally
representative hits, including BRD5631, as well as one hit lacking
an amine (Fig. 1D), that display a range of activities in the GFP-
LC3 assay (Fig. 1 A and B and SI Appendix, Fig. S3A) and
mCherry-GFP-LC3 assay (SI Appendix, Fig. S1). As expected,
control compounds that inhibit lysosomal proteases directly
(E64d/pepstatin A) or indirectly by increasing lysosomal pH
[bafilomycin A1 (BafA1) and chloroquine (CQ)] significantly de-
creased both DQ-BSA punctae number and intensity. In contrast,
none of the selected hits reduced either the number or intensity of
DQ-BSA punctae at doses that induce GFP-LC3 punctae (Fig. 2A
and SI Appendix, Fig. S3B). Furthermore, the compounds did not
disrupt accumulation of a fluorescent basic amine probe used to
stain acidic compartments (LysoTracker Red; Fig. 2B and SI
Appendix, Fig. S3C) or significantly affect viability at autophagy-
modulating doses (<10% effect; SI Appendix, Fig. S3D) (32).
These data suggest that BRD5631 and other hits do not increase
E4282 | www.pnas.org/cgi/doi/10.1073/pnas.1512289112 Kuo et al.
GFP-LC3 punctae formation by broadly disrupting lysosomal
function.
We then characterized BRD5631 and the other selected com-
pounds more deeply in mechanistic and functional assays for
autophagy. Consistent with the results from microscopy, we found
that BRD5631 led to increased levels of LC3-II by Western blot
(Fig. 2C). When cotreated with the vacuolar H+-ATPase inhibitor
BafA1 (a known late-stage inhibitor of autophagy), BRD5631
was able to increase LC3-II levels above those observed with
BafA1 alone, suggesting that BRD5631 stimulates formation of
new autophagosomes (Fig. 2C). These data are consistent with its
ability to increase numbers of autolysosomes (mCherry+/GFP−) in
the mCherry-GFP-LC3 assay. Similar results were observed with
other screening hits to a lesser degree (SI Appendix, Fig. S3E),
with the exception of BRD34009, which induced LC3-II forma-
tion but showed modest inhibitory activity in the mCherry-GFP-
LC3 assay.
Because inhibition of mTOR signaling is known to promote
autophagy, we determined whether the compounds affected
phosphorylation of mTOR-regulated proteins, including p70 S6
kinase 1 (S6K1) (Thr389) (33) and the autophagy-initiating ki-
nase ULK1 (Ser757) (34). Consistent with previous reports (33,
35), we confirmed that treatment with the mTOR kinase in-
hibitor torin1 and mTOR pathway modulator rottlerin led to
decreased phosphorylation of S6K1 and ULK1 (Fig. 2D). In
contrast, BRD5631 and other screening hits did not significantly
affect S6K1 or ULK1 mTOR-dependent phosphorylation levels
at 10 μM, suggesting that they do not enhance autophagy by
directly inhibiting mTOR or the mTOR signaling pathway.
BRD5631 Decreases the Presence of Aggregates in Cells Expressing
Poly-Q Repeats (eGFP-HDQ74).We assessed the ability of BRD5631
to promote clearance of an autophagic cargo using the well-
established substrate, mutant huntingtin (eGFP-HDQ74) (36).
Transient overexpression of eGFP-HDQ74 in autophagy-deficient
cells [Atg5−/− mouse embryonic fibroblasts (MEFs)] causes
increased aggregate formation compared with their wild-type
counterparts (Atg5+/+MEFs) due to its inability to be degraded by
autophagy (37). Treatment with BRD5631 significantly reduced
the number of eGFP-HDQ74-positive cells in Atg5+/+ MEFs; this
reduction was not observed in Atg5− /− MEFs, suggesting
BRD5631 promotes clearance of mutant huntingtin in an auto-
phagy-dependent manner (Fig. 2E). We also measured changes in
Fig. 1. HTS identifies DOS-derived small-molecule autophagy modulators. (A and B) HeLa cells stably expressing GFP-LC3 were treated with compounds in
8-point dose (4 h), and the number of GFP punctae per cell was quantified by fluorescence microscopy and automated image analysis. Representative images
of cells treated with DMSO, PI-103 (2.5 μM), BRD5631 (10 μM), or BRD34009 (10 μM) are shown. Data points of dose curves are presented as the mean ± SD, n = 3
from a representative experiment. (C) Results of GFP-LC3 punctae formation assay show that BRD5631 analogs corroborate structure-activity relationship trends
observed in the primary HTS. Data are the mean ± SD of three independent experiments. (D) Chemical structures of five prioritized compounds.
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the level of another specific autophagy substrate, p62 (38), in re-
sponse to BRD5631 in these cells. Under steady-state conditions,
Atg5−/−MEFs displayed increased p62 levels compared with Atg5+/+
MEFs. BRD5631 substantially increased LC3-II levels in Atg5+/+
MEFs as expected; however, it increased p62 levels in Atg5+/+MEFs
without any detectable effect in Atg5−/− MEFs (SI Appendix,
Fig. S4A). Transcriptional up-regulation of p62 in response to
autophagy activation has been previously reported (39), compli-
cating interpretation of its levels as a readout for autophagic flux.
We also observed that BRD5631 increased the transcript level of
p62 in Atg5+/+ MEFs (SI Appendix, Fig. S4B), suggesting a com-
plex effect of BRD5631 on p62 levels in this cellular context.
BRD5631 Suppresses NPC1-Induced Cell Death in a hiPSC-Derived
Neuronal Model of Niemann–Pick Type C1 Disease. We have re-
cently shown that small-molecule enhancers of autophagy, such as
CBZ, can rescue impairment of autophagic flux observed in
NPC1, a lipid/lysosomal storage disease exhibiting accumu-
lation of cholesterol in the late endosomal/lysosomal com-
partments and associated with degeneration of the cerebellum and
liver in patients (17, 18). These enhancers also suppress cell death
in NPC1 patient-specific hiPSC-derived neuronal and hepatic
cells, which normally display cholesterol accumulation, impaired
autophagic flux, and increased cell death in the absence of any
external stressors relative to control cells (18). Using this
system, we assessed the ability of the prioritized compounds to
rescue the NPC1-associated loss of cell viability relative to the
positive control (100 μM CBZ). We found that BRD5631,
BRD2716, and BRD34009 significantly reduced cell death in
NPC1 hiPSC-derived neurons (Fig. 3A). Interestingly, these
compounds did not rescue increased cell death in NPC1 hiPSC-
derived hepatic cultures (SI Appendix, Fig. S5). We further ex-
amined the impact of these compounds on autophagic flux by
measuring p62 levels in NPC1 hiPSC-derived neurons, which
display accumulation of this autophagy substrate relative to con-
trol cells (18) (Fig. 3B). In contrast to the results obtained in
MEFs, treatment with BRD5631, BRD2716, and BRD34009 re-
duced levels of endogenous p62 in NPC1 neuronal cells (Fig.
3B). The correlation between the neuroprotective effects of
BRD5631, BRD2716, and BRD34009 and clearance of autophagy
substrates in NPC1 neuronal cells suggests a possible role for in-
creased autophagic flux in rescuing cells from the disease phenotype.
BRD5631 Enhances Bacterial Clearance in an Autophagy-Dependent
Manner. Several bacterial pathogens are selectively targeted by
autophagy for degradation (bacterial xenophagy), including Sal-
monella, Shigella, Mtb, and group A Streptococcus (40). Further-
more, compromised antibacterial autophagy has been implicated
by studies of disease-associated genes (ATG16L1, IRGM), poten-
tially contributing to inflammation via an increased microbial
burden within the intestinal epithelium (4). To determine if
BRD5631 and other hits can promote antibacterial autophagy, we
first measured their ability to inhibit bacterial replication using a
bioluminescent strain of Salmonella enterica serovar Typhimurium
infecting mammalian epithelial cells (HeLa). Three of five priori-
tized autophagy modulators (BRD5631, BRD34009, BRD2716)
inhibited Salmonella replication over time, beginning as early as 3 h
postinfection (p.i.), to similar or greater levels than an autophagy
modulator reported to have anti-Salmonella activity, trifluoperazine
(TFP) (41) (Fig. 4A and SI Appendix, Fig. S6 A and B). Traditional
CFU assays confirmed the results of the luminescence assay (SI
Appendix, Fig. S6C). None of the prioritized small molecules dis-
played general bactericidal activity in the absence of host cells or
cytotoxicity to host cells at the concentration used for the clearance
assay (SI Appendix, Fig. S6 D and E).
To assess the dependence of replication inhibition on auto-
phagy, we tested the antibacterial activity of hits on a clonal
ATG16L1-deficient HeLa cell line generated using the clustered
regularly interspaced short palindromic repeats (CRISPR)-Cas9
system (42) (SI Appendix, Fig. S6F). ATG16L1 forms a complex
with ATG5-ATG12 conjugates to promote conjugation of LC3
to phosphatidylethanolamine and elongation of autophagosomal
membranes (43). As expected, ATG16L1-deficient cells dis-
played significantly greater levels of bacterial replication than
the parental line (SI Appendix, Fig. S6G), and an antibiotic that
directly targets bacteria [chloramphenicol (CP)] was able to
Fig. 2. Functional characterization of autophagy modulators. (A) Compounds
were evaluated in the DQ-BSA assay. BafA1 (100 nM), CQ (50 μM), E64d/pepA
(10 μg/mL each), PI-103 (10 μM), and DOS compounds (10 μM each). Data are
presented as mean ± SD, n = 3. (B) Compounds were evaluated in the Lyso-
Tracker assay in 8-point dose by twofold serial dilution from the following
starting concentrations: PI-103 and DOS compounds (20 μM each), BafA1
(200 nM), CQ (100 μM). Data are presented as average area under the curve ±
SD, n = 2. (C) HeLa cells were treated with indicated compounds (7 h). For the
last 4 h, either DMSO or BafA1 (100 nM) was added, then protein samples
were harvested for immunoblot analysis. (D) HeLa cells were treated with
compounds (4 h), then harvested for immunoblot analysis. (E) Atg5+/+ and
Atg5−/− MEFs were transfected with eGFP-HDQ74 construct followed by
treatment with ±BRD5631 (10 μM; 48 h). Percentage of eGFP+ cells with eGFP-
HDQ74 aggregates was quantified by fluorescence microscopy. Data are pre-
sented as mean ± SEM, n = 3. *P < 0.05, ns, not significant, compared to
untreated Atg5+/+ MEFs, unless indicated otherwise, unpaired Student t test.
All data are representative of multiple independent experiments.
Fig. 3. A subset of autophagy modulators rescue impairments in NPC1
disease hiPSC-derived neurons. (A) Control (WIBR3-derived) neurons were
treated with DMSO, and NPC1 hiPSC (WIBR-IPS-NPC1–derived) neurons were
treated with DMSO, DOS compounds (10 μM each), or CBZ (100 μM) for
3 days. Cell death was quantified using TUNEL assay and apoptotic nuclear
morphology. Data are presented as the mean ± SD and are representative of
two independent experiments, each run in triplicate. (B) Cell populations
treated as described in Awere subjected to immunoblot analysis. All samples
were run in the same gel and blotted at the same time. The line denotes
where one intervening lane was excised. Densitometric analysis shows p62
levels relative to GAPDH in NPC1 hiPSC-derived neurons. The control con-
dition was set to 100%, and data represent the mean ± SEM of samples from
the same experiment in A. *P < 0.05, **P < 0.01, ***P < 0.001, ns, not sig-
nificant, compared to DMSO-treated NPC1 cells, unless indicated otherwise,
unpaired Student t test.
E4284 | www.pnas.org/cgi/doi/10.1073/pnas.1512289112 Kuo et al.
suppress bacterial replication in both cell lines. When we treated
the ATG16L1-deficient cells with BRD5631 and other hits, no
reduction in bacterial replication was observed (Fig. 4A and SI
Appendix, Fig. S6A). Although the interpretation may be com-
plicated by the increased rate of replication in the knockout cells,
these data suggest that autophagy is required for the effect of
BRD5631 on bacterial clearance.
To determine whether compounds that inhibit replication of
intracellular Salmonella affect its association with the antibac-
terial autophagy machinery, we measured the colocalization of
dsRed-expressing Salmonella with both LC3 and NDP52, an
adaptor protein that targets galectin-8- or Ub-coated Salmonella
to autophagy (40). As reported previously, treatment with TFP
enhanced the maximal colocalization of Salmonella and LC3 and
NDP52 observed at 1 h p.i., which was maintained at later time
points (4 h p.i.) when the colocalization events subsided in
vehicle control-treated cells (Fig. 4B). BRD5631 was able to
moderately enhance colocalization events at 1 h p.i. and later
time points to a higher level than TFP (Fig. 4B).
The CD risk allele ATG16L1 T300A has been linked to im-
paired colocalization of Salmonella and LC3 in genetically
modified HeLa cells (44). To determine if BRD5631 is able to
overcome defects in colocalization of Salmonella and LC3 in the
presence of this risk allele, we performed the colocalization assay
in ATG16L1-deficient HeLa cells reconstituted with wild-type
ATG16L1 or ATG16L1 T300A (SI Appendix, Fig. S6H). As
reported, LC3 recruitment was diminished in the absence of
ATG16L1. Reintroducing ATG16L1 T300A partially rescued
the colocalization ratio, but significantly less than the ratio in
cells reconstituted with wild-type ATG16L1 (Fig. 4C). TFP and
BRD5631, as well as the autophagy-inducing peptide Tat-Beclin1,
moderately enhanced the colocalization of LC3 and Salmonella
in ATG16L1 T300A cells (Fig. 4C). Similarly, BRD5631
and TFP inhibited bacterial replication in the presence of
ATG16L1 T300A (Fig. 4D).
BRD5631 Suppresses IL-1β Secretion in an Autophagy-Dependent
Manner. Previous studies have demonstrated a role for autophagy
in the regulation of IL-1β levels. Although activation of autophagy
by rapamycin has been shown to induce pro–IL-1β degradation and
decreased IL-1β secretion in macrophages (21), the effect of
mTOR-independent modulation of autophagy on cytokine pro-
duction has not been systematically explored. To determine whether
the mTOR-independent autophagy modulators discovered in our
screen could regulate IL-1β release in response to microbial TLR4
and NOD2 ligands, we tested BRD5631 and other hits in IFN-
γ–primed macrophages stimulated with lipopolysaccharide (LPS)
and muramyl dipeptide (MDP). LPS-MDP stimulated robust IL-1β
secretion from immortalized bone marrow-derived macrophages
(Fig. 5A). The antiinflammatory glucocorticoid dexamethasone
(Dex) and the caspase1 inhibitor VX-765, compounds that target
transcriptional and posttranslational steps in IL-1β production, re-
spectively, significantly reduced IL-1β release (Fig. 5A). All tested
DOS-derived autophagy modulators reduced IL-1β secretion at
10 μM (Fig. 5A). Furthermore, the effect of these compounds on
IL-1β secretion was dose-dependent and not associated with cyto-
toxicity (SI Appendix, Fig. S7 A and B).
To determine whether the observed reduction in IL-1β release
was autophagy-mediated, we assayed their IL-1β–repressive activity
in immortalized bone marrow-derived macrophages in which Atg5
had been deleted by CRISPR. Consistent with Atg5 deletion, these
cells show reduced levels of ATG5-ATG12 conjugates and LC3-II
(SI Appendix, Fig. S7C). IL-1β secretion following LPS-MDP
stimulation was significantly higher in the Atg5 CRISPR line com-
pared with parental controls, consistent with previous reports for
other autophagy-deficient cell models (5) (SI Appendix, Fig. S7D).
All four autophagy modulators suppressed IL-1β release in the
parental cell line with little to no effect in the Atg5 CRISPR cell
Fig. 4. Autophagy modulators clear invasive bacteria. (A) Salmonella sur-
vival in cells was assessed in the bioluminescent bacterial replication assay.
Luminescence intensity in live cells was measured at each indicated time
point, and fold replication values were calculated for each well as raw lu-
minescence intensity divided by the intensity at 1 h p.i. Data are presented as
mean ± SD, n = 4 from a representative experiment. (B) HeLa cells were
pretreated with compound (3 h) and infected with Salmonella. Cells were
then fixed and subjected to immunostaining at indicated time points.
Colocalization ratios were calculated to compare Salmonella colocalized
with LC3 or NDP52 to total Salmonella. Data are presented as mean ± SD,
n = 4 from a representative experiment. (C) ATG16L1-deficient HeLa cells
were reconstituted with ATG16L1 T300T (T) or T300A (A), seeded on cover-
slips, pretreated, infected, and fixed and stained (1 h p.i.). Data are presented
as mean ± SD of three independent experiments. At least 100 bacteria
per coverslip and triplicated coverslips in each experiment were scored. (D)
ATG16L1-deficient HeLa cells were reconstituted as described in C and in-
fected, treated, and imaged as described in A. In A–D, all compounds were
treated at 10 μM. *P < 0.05, **P < 0.01, ***P < 0.001, ns, not significant,
unpaired Student t test.
Fig. 5. Autophagy modulators suppress IL-1β secretion. (A) IL-1β secretion was
measured in immortalized murine bone marrow-derived macrophages primed
with IFN-γ (100 ng/mL) (16 h) and stimulated with LPS (10 ng/mL)-MDP
(10 μg/mL) (24 h), both in the presence of Dex (5 μM), VX-765 (20 μM), or DOS
compounds (each 10 μM). Secreted IL-1β was detected by ELISA. Data are pre-
sented as mean ± SD, n = 3 from a representative experiment of three in-
dependent experiments. (B) IL-1β secretion was measured in murine splenic
CD11b+ macrophages (ATG16L1 WT or T300A) primed with IFN-γ (100 ng/mL)
(6 h) and then treated with IFN-γ (100 ng/mL)-LPS (2 ng/mL)-MDP (10 μg/mL)
(24 h), both in the presence of Dex, VX-765, or BRD5631. Secreted IL-1β was de-
tected by ELISA. Data are presented as mean ± SD, n = 4 mice. ND, not detected.
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line, suggesting that activities for these compounds are autophagy-
mediated (Fig. 5A).
The CD risk allele ATG16L1 T300A has also been linked to
increased levels of IL-1β in patients (45). To determine whether
DOS-derived compounds are able to reduce IL-1β levels in the
presence of this disease allele, we evaluated the activity of the
compounds in ATG16L1 T300A cells derived from knock-in
mice. Consistent with previous observations (5), splenic CD11b+
macrophages from ATG16L1 T300A mice demonstrated increased
IL-1β release compared with wild-type controls (Fig. 5B). In-
terestingly, BRD5631 significantly reduced the elevated IL-1β levels
observed in ATG16L1 T300A cells (Fig. 5B).
Discussion
Human genetic studies have linked autophagy to several dis-
eases, and depending on the context, impairment of autophagy
can lead to distinct phenotypes in specific cell types and organ
systems. For example, CD-associated genetic variants in ATG16L1
have implicated autophagy defects as contributing to compromised
antibacterial activity in epithelial cells, elevated IL-1β secretion
from monocytes/macrophages, reduced Paneth cell function, and
impaired antigen presentation in dendritic cells (4). These obser-
vations, as well as examples from other diseases, such as Niemann–
Pick disease, TB infection, α1-antitrypsin deficiency, and neu-
rodegenerative disorders, suggest that small-molecule modula-
tion of canonical and/or selective autophagy in disease-relevant
cell types could be therapeutically beneficial (1, 17).
Though several small-molecule enhancers of autophagy have
been described, the mechanisms of action necessary to impact these
disease-related immune pathways are not well understood. Auto-
phagy induction via inhibition of mTOR signaling has been shown
to promote the autophagic clearance of bacteria (20) and suppress
IL-1β secretion by targeting pro–IL-1β for degradation (21).
Though mTOR modulators are used therapeutically (10), they
have been linked to several dose-limiting adverse effects, sug-
gesting the importance of discovering novel, mTOR-independent
modulators of autophagy. To this end, we have identified a set of
novel DOS-derived small molecules that promote autophagy in-
dependently of mTOR, and that modulate a number of cell type-
specific disease phenotypes.
Several compounds discovered in our screen for autophagy en-
hancers contain a biphenyl or diphenyl alkyne group and a basic
amine. Although basic amines are thought to bias compounds for
accumulation in acidic cellular compartments such as lysosomes
(46), our data suggest that these molecules do not reduce cell
viability, disrupt lysosomal protease function, or perturb accumu-
lation of LysoTracker Red, making them distinct from known
lysosomotropic molecules. It is certainly possible that the com-
pounds accumulate at higher concentrations within acidic com-
partments and exert a specific function on a lysosomal protein or
signal to regulate autophagy. Indeed, an analogous model has been
proposed to underlie the activity of functional inhibitors of acid
sphingomyelinase (ASM), which cause extrusion and consequent
inactivation of ASM from the inner lysosomal membrane (47).
Whether small molecules that operate through such a mechanism
could be exploited in a therapeutic context remains unclear, but it
is worth noting that similar structural moieties are present within
previously reported FDA-approved enhancers of autophagy [e.g.,
calcium channel modulators (niguldipine) and D2 receptor mod-
ulators (TFP)] (48), arguing that such agents can be tolerated by
humans. Further studies are needed to investigate how BRD5631
promotes autophagy in cells, and which regulatory pathways are
involved in this process.
Importantly, BRD5631 appears to modulate several disease-
associated phenotypes, including decreasing numbers of aggre-
gate-expressing cells, reducing apoptosis of neurons in NPC1
models (at 10-fold lower concentration than CBZ), enhancing
bacterial clearance, and decreasing IL-1β secretion. As such,
studying BRD5631 and its mechanism of action may reveal
therapeutically beneficial mechanisms for modulating autophagy
in the context of human disease. For example, in CD patients, the
risk allele ATG16L1 T300A has been linked to elevated IL-1β
levels (45). Furthermore, the ATG16L1 T300A knock-in mouse
model recapitulates many of the autophagy-relevant phenotypes
observed in CD patients, including the overproduction of IL-1β in
response to microbial ligands, providing a valuable system to test
the impact of our compounds in the presence of a CD risk allele
(5). We demonstrated that BRD5631 robustly suppressed the el-
evated IL-1β observed in ATG16L1 T300A macrophages from
knock-in mice, revealing this molecule can modulate relevant
phenotypes in the context of a human disease allele. Given
BRD5631 itself is not well-tolerated in vivo (data not shown), the
successful development of analogs that separate toxicity from
autophagy enhancement would be a critical step to determine
whether BRD5631 modulates autophagy in a therapeutically
relevant manner.
The evaluation of autophagy enhancement as a therapeutic
strategy will ultimately require careful investigation of its com-
plex relationship to cell death and cell survival in different
physiological contexts. For example, autophagy has been pro-
posed to promote cell survival in the context of cancer and cell
death in the context of hypoxia–ischemia. Small-molecule probes
that modulate autophagy will be critical for studying the pathway
in different disease-relevant contexts and for understanding
how it can be targeted to yield new medicines that are both safe
and effective.
Materials and Methods
For the primary HTS, HeLa cells stably expressing GFP-LC3 were seeded in 384-
well plates (16 h) and treated with compounds (4 h). Cells were fixed in 3.7%
(wt/vol) paraformaldehyde for 15 min, washed, and DNA stained with
Hoechst 33342 (Sigma). High-throughput imaging (20×) was performed on
an ImageXpress Micro automated microscope (Molecular Devices) and the
number of GFP punctae per cell was quantified using MetaXpress high-
content image analysis software. For the DQ-BSA assay, HeLa cells were
pulsed with DQ-BSA (Life Technologies) (1 h), DQ-BSA was washed away,
and cells were treated with compounds (6 h). Nuclei were stained with
Hoechst 33342 (30 min) and live cells imaged as above. For the LysoTracker
assay, compound-treated (4 h), live HeLa cells were stained with LysoTracker
Red dye (Life Technologies) and Hoechst 33342 (1 h) and imaged as above.
The percentage of eGFP+ cells with eGFP-HDQ74 aggregates was assessed as
described (37). Neurons were generated from neural precursors, which were
derived from hESCs and NPC1 hiPSCs using an embryoid body-based pro-
tocol, and analysis of neuronal cell death was performed as described (18).
Bioluminescent bacterial replication and CFU assays were performed as de-
scribed (41). For colocalization assays, HeLa cells were seeded in antibiotic-
free media (16 h). After compound pretreatment (3 h), cells were infected
with Salmonella expressing DsRed (Clontech), retreated with compounds,
and at indicated p.i. time points, cells were fixed, stained, and imaged to
quantify the number of LC3+ and NDP52+ bacteria. iBMDM line was gen-
erated from BMDMs infected with a J2 retrovirus carrying the v-myc and
v-raf oncogenes and cultured for 14 d in M-CSF-conditioned media followed
by 14 d without M-CSF. CD11b+ cells were isolated by positive selection using
CD11b microbeads (Miltenyi) and spleens derived from C57 BL/6 Atg16l1wt/wt
and Atg16l1T300A/T300A mice. IL-1b levels were measured by ELISA (BD Bio-
sciences). T300A knock-in mice were generated and maintained as pre-
viously described (5). Animals were housed in a pathogen-free facility, and
all procedures were performed in accordance with the institutional animal
care and use committee at Massachusetts General Hospital. Additional de-
tails on reagents, chemical synthesis, and experimental protocols are avail-
able in SI Appendix.
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